Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
46.96
-0.33 (-0.70%)
At close: Jun 13, 2025, 4:00 PM
46.01
-0.95 (-2.02%)
After-hours: Jun 13, 2025, 7:13 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $22.10M in the quarter ending March 31, 2025, with 114.83% growth. This brings the company's revenue in the last twelve months to $58.89M, down -25.85% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$58.89M
Revenue Growth
-25.85%
P/S Ratio
61.72
Revenue / Employee
$313,218
Employees
188
Market Cap
3.06B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KYMR News
- 8 days ago - Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial - Barrons
- 11 days ago - Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data - Seeking Alpha
- 11 days ago - Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Barrons
- 11 days ago - Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
- 14 days ago - Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 - GlobeNewsWire
- 15 days ago - Kymera Therapeutics to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 25 days ago - Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff - Seeking Alpha